Slide 1: Investors' Presentation
RPG LIFE SCIENCES An @FPG Company Investors’ Presentation
Slide 2: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 3: RPG Life Sciences Overview
RPG Life Sciences Overview RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Leader in Immunosuppressants Domestic Formulations
Slide 4: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies Key Products Immunosuppressant Portfolio Text Book Brands New Portfolio • Nephrology Specialty Chronic Azathioprine • Rheumatology Azathioprine Domestic • Oncology Spironolactone Trastuzumab Formulations • Orthopaedics Vildagliptin Adalimumab • Gastr
Slide 5: Key Financials, Business Highlights & Strategy
Key Financials, Business Highlights & Strategy
Slide 6: Key Financial Highlights
Key Financial Highlights (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 389.1 70.8 53.6 375.6 59.9 41.8 34.4 330.2 15.1 10% 16% 18% 5% 11% 14% FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 PAT & PAT Margin EPS 40.0 24.2 29 17.5 10.8 6.5 3
Slide 7: Key Financial Highlights: Balance Sheet Ratios
Key Financial Highlights : Balance Sheet Ratios ROCE% ROE% Debt/Equity Ratio 23.6% 24.3% 16.4% 18.5% 0.22 11.0% 6.7% 0.06 0.01 FY19 FY20 FY21 FY19 FY20 FY21 FY19 FY20 FY21 Company becomes Debt-free
Slide 8: RPG Life Sciences ICRA Rating Upgradation
RPG Life Sciences ICRA Rating Upgradation Long term rating upgraded to A from A- Short term rating upgraded to A1 from A2+ Outlook on long term rating has been retained as Stable. The rating upgradation factors: ➢ Considerable improvement in the operating performance on the back of • Improvement in
Slide 9: Business Segment-wise Performance
Business Segment-wise Performance Net Sales (Rs Crs) • Domestic Formulations contributed 62% to total Sales of FY21 • Sustained sales with +ve growth despite Covid headwinds : Deeper Acute 240.5 242.1 195.8 Domestic Portfolio deceleration, Transplant, Dialysis centres/Clinics closure, smaller Formul
Slide 10: Domestic Formulations
Domestic Formulations Highlights • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leader in Immunosuppressant category • Good Customer Coverage - Cardiolog
Slide 11: International Formulations
International Formulations Highlights • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and business relationship with some
Slide 12: APIs
APIs Highlights • High Value, Low Volume Niche APIs • Mature Stable Molecules • Provides backward integration to International Formulations business • Footprints across geographies - LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc • Strong customer focus - Long lasting relati
Slide 13: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities
Slide 14: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the Domestic and Emerging Markets • Multipurpose plant with dedicated product lines for Oral Dosage forms including Tablets, Liquids and Powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 15: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All Critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly Internal audit of all plants by CQA to Canada, UK, EU, Australia and Emerging markets • All critical deviations, change controls and market
Slide 16: Operational Highlights
Operational Highlights An FPG Company
Slide 17: RPG Life Sciences response to COVID-19
RPG Life Sciences response to COVID-19 A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our Plants did not stop even for a single day. Every patient, who asked for our critical medicines, serviced by
Slide 18: New Digitalization Initiatives to Transform Business
New Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc Anytime, Anywhere Doctor Sup
Slide 19: People Initiatives to build Performance Culture with focus on Happiness
People Initiatives to build Performance Culture with focus on Happiness I Love My Work I Feel Valued I am Growing RPGLS Heroes Outperformance We Skill. You Grow. You Excel. We Applaud. Recognition Competency Building Motivation Continuum Continuum Akanksha Career Development Signature People Initiat
Slide 20: Awards & Recognitions
Awards & Recognitions Z An @>FRPG Company = —————___——— RPG LIFE SCIENCES
Slide 21: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Prestigious Awards from IDMA - Indian Drug Manufacturer’s Association in January 2020 (consists of 1000+ pharma companies) IDMA Quality Excellence IDMA Corporate Citizen Award 2019 Award 2019 (GOLD AWARD) IDMA Margi Patel Choksi Memorial Best Patent Awar
Slide 22: RPG Life Sciences is one of India's Best Workplaces in 2020
RPG Life Sciences is one of the India’s Best Workplace in 2020 – Amongst Top 100 • Ranked 85 amongst India's 100 Best Companies to Work For 2020 • One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work® Institute
Slide 23: Media Recognition
Media Recognition • Not a single day Plant stoppage • Home Delivery of critical life saving medicines to all the patients
Slide 24: An FPG Company RPG LIFE SCIENCES
00006 000 Z An FPG Company RPG LIFE SCIENCES